- 著者
- Shigeru Ishida Hanae Morikawa Hiroyuki Watanabe Toshikazu Tsuji Takeshi Sugio Yasuo Mori Toshihiro Miyamoto Satohiro Masuda Koichi Akashi Nobuaki Egashira
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Biological and Pharmaceutical Bulletin (ISSN:09186158)
- 巻号頁・発行日
- vol.43, no.3, pp.488-492, 2020-03-01 (Released:2020-03-01)
- 参考文献数
- 19
- 被引用文献数
- 1
The intravenous injection of bendamustine often induces venous irritation, which reduces patients’ QOL. We previously reported that the dilution of the final volume of bendamustine from 250 to 500 mL significantly decreased the incidence of venous irritation. However, the influence of this change on the therapeutic efficacy of bendamustine remains unclear. Therefore, the aim of this study was to evaluate the efficacy and safety profiles of bendamustine at different dilutions of the final volume, comparing with the correspondences of previous studies. Thirty-four patients, who received a total of 161 courses of bendamustine and rituximab chemotherapy, were included in this study. The overall response rate of this regimen was 94.1% in this study, which was comparable to that reported in the BRB study (94.2%, a phase II study of bendamustine plus rituximab therapy in Japanese patients). Additionally, the median progression-free survival was not inferior to that reported in the BRB study. Bendamustine-induced venous irritation was observed in 17.6% of the patients during the first treatment cycle administered at a final volume of 500 mL, and was found to be lower than that observed in the control, where bendamustine was administered at a final volume of 250 mL (85.7%). These results suggest that diluting bendamustine to 500 mL, but not to 250 mL, reduces the incidence of venous irritation without a negative impact on its therapeutic efficacy; thus, this simple strategy may be beneficial to ensure efficacy and safety in patients receiving regimens including bendamustine.
- 著者
- Michihiro FUJIWARA Nobuaki EGASHIRA Kenichi MISHIMA Katsunori IWASAKI
- 出版者
- 和漢医薬学会
- 雑誌
- Journal of Traditional Medicines (ISSN:18801447)
- 巻号頁・発行日
- vol.24, no.5, pp.149-155, 2007 (Released:2007-12-28)
- 参考文献数
- 60
- 被引用文献数
- 1
これまで我々が行ってきた当帰芍薬散のアルツハイマー病や脳血管性障害に関する基礎研究を概説した。 当帰芍薬散は抗コリン薬による空間記憶障害を改善し, アセチルコリン機能を亢進する。 我々はこの作用における活性成分の探索を行い, ブタノール画分に含まれるベンゾジアゼピン受容体インバースアゴニストである Ang-S-1 であることを見出した。 さらに, 我々は当帰芍薬散が背側海馬におけるアセチルコリン遊離や脳血流を増加し, アルツハイマー病の原因蛋白であるアミロイドβ蛋白による神経障害を保護することも明らかにした。 一方, アルツハイマー病や脳血管性障害の動物モデルの検討において, 当帰芍薬散は繰り返し脳虚血ラットにおけるアポトーシスを伴った空間記憶障害を虚血後の投与によって予防することやアミロイドβ蛋白を背側海馬に注入した卵巣摘出ラットにおける空間記憶障害およびアセチルコリン遊離の低下を予防することも我々は証明した。 以上, 当帰芍薬散はアルツハイマー病や脳血管性障害の動物モデルに対して神経活性や神経保護作用を有しており, これらの疾患の治療に有用であることが考えられた。
- 著者
- Nobuaki Egashira Ai Nogami Katsunori Iwasaki Ayumi Ishibashi Naoki Uchida Kotaro Takasaki Kenichi Mishima Ryoji Nishimura Ryozo Oishi Michihiro Fujiwara
- 出版者
- The Japanese Pharmacological Society
- 雑誌
- Journal of Pharmacological Sciences (ISSN:13478613)
- 巻号頁・発行日
- vol.116, no.3, pp.316-320, 2011 (Released:2011-07-15)
- 参考文献数
- 15
- 被引用文献数
- 32 33
In the present study, we investigated the effect of the Kampo medicine Yokukansan (YKS) on pentobarbital-induced sleep in group-housed and socially isolated mice. Socially isolated mice showed shorter sleeping time than the group-housed mice. YKS (300 mg/kg, p.o.) prolonged the pentobarbital-induced sleeping time in socially isolated mice without affecting pentobarbital sleep in group-housed mice. The prolongation of sleeping time by YKS was reversed by bicuculline (3 mg/kg, i.p.) and flumazenil (3 mg/kg, i.p.), but not WAY100635. These findings suggest that the GABAA – benzodiazepine receptor complex, but not 5-HT1A receptors, is involved in the reversal effect of YKS on the decrease of pentobarbital sleep by social isolation.
- 著者
- Tassadit Belabbas Takaaki Yamada Yuichi Tsuchiya Kimitaka Suetsugu Nobuaki Egashira Ichiro Ieiri
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Chemical and Pharmaceutical Bulletin (ISSN:00092363)
- 巻号頁・発行日
- vol.69, no.7, pp.646-651, 2021-07-01 (Released:2021-07-01)
- 参考文献数
- 17
- 被引用文献数
- 2
With the aim of studying the pharmacokinetics of letermovir, which is a newly developed antiviral agent for human cytomegalovirus, a rapid and simple ultra-performance liquid chromatography coupled with mass spectrometry (UPLC/MS) method was developed and validated for the quantification of letermovir in human plasma. Separation was performed in reverse phase mode using an ACQUITY UPLC BEH C18 column (130 Å, 1.7 µm, 2.1 × 50 mm) at a flow rate of 0.3 mL/min, 10 mM ammonium acetate–0.1% formic acid solution as mobile phase A, and acetonitrile as mobile phase B with a gradient elution. The method was validated over a linear range of 10–1000 ng/mL with a coefficient of determination (R2) >0.99 using weighted linear regression analysis. The intra- and inter-assay accuracy (nominal%) and precision (relative standard deviation%) were within ±15 and ≤15%, respectively. The specificity, recovery, matrix effect, stability, and dilution integrity of this method were also within acceptable limits. This method could be useful in studying the pharmacokinetics and pharmacodynamics, as well as performing the therapeutic drug monitoring of letermovir.
- 著者
- Shigeru Ishida Ken Masuguchi Takehiro Kawashiri Toshikazu Tsuji Hiroyuki Watanabe Sayuri Akiyoshi Makoto Kubo Satohiro Masuda Nobuaki Egashira
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Biological and Pharmaceutical Bulletin (ISSN:09186158)
- 巻号頁・発行日
- vol.43, no.4, pp.663-668, 2020-04-01 (Released:2020-04-01)
- 参考文献数
- 38
- 被引用文献数
- 1 2
Hypersensitivity reactions, including anaphylaxis, are common side effects associated with docetaxel treatment in breast cancer patients. However, preventive measures have not yet been established. In this study, we retrospectively analyzed the risk factors for developing anaphylaxis in 182 female breast cancer patients treated with docetaxel. We found that 6.6% of all patients (n = 12) experienced anaphylaxis. Multivariate analyses indicated that concentration of docetaxel higher than 0.275 mg/m2/mL, docetaxel dose rate higher than 1.15 mg/m2/min, and white blood cell count less than 4290 cells/mL are risk factors for developing docetaxel-related anaphylaxis. In particular, concentrations of docetaxel or doses per administration time were associated with a high odds ratio (11.88 or 11.60) for docetaxel-related anaphylaxis. Moreover, patients receiving doses in 250 mL volume experienced anaphylaxis more frequently than those receiving doses in 500 mL (7.0 vs. 0.9%, p = 0.0236). Additionally, patients receiving treatments over 60 min tended to experience anaphylaxis more frequently than those who were treated over 90 min (6.7 vs. 1.1%, p = 0.0637). The present results indicate that high docetaxel concentrations, high dose rates, and low white blood cell counts are risk factors for developing docetaxel-related anaphylaxis, and administering docetaxel diluted in 500 mL over 90 min may limit docetaxel-induced hypersensitivity reactions.
- 著者
- Nobuaki Egashira Kazuhide Hayakawa Megumi Osajima Kenichi Mishima Katsunori Iwasaki Ryozo Oishi Michihiro Fujiwara
- 出版者
- The Japanese Pharmacological Society
- 雑誌
- Journal of Pharmacological Sciences (ISSN:13478613)
- 巻号頁・発行日
- vol.105, no.2, pp.211-214, 2007 (Released:2007-10-17)
- 参考文献数
- 11
- 被引用文献数
- 45 64
We investigated the involvement of γ-aminobutyric acidA (GABAA) receptors in the neuroprotective effect of γ-glutamylethylamide (theanine), a component of Japanese green tea, following a 4-h middle cerebral artery (MCA) occlusion in mice. Theanine (1 mg/kg) reduced the size of the cerebral infarct and alterations of NeuN, GFAP, and Iba 1 expression levels at 24 h after MCA occlusion. This neuroprotective effect of theanine was prevented by bicuculline (GABAA-receptor antagonist, 10 mg/kg) but not 3-mercaptopropionic acid (glutamate decarboxylase inhibitor). These results suggest that the neuroprotective effect of theanine is mediated, at least in part, by GABAA receptors.